# Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )

> **NCT07340723** · PHASE2 · RECRUITING · sponsor: **Daihong Liu** · enrollment: 168 (estimated)

## Conditions studied

- GVHD,Acute
- Stem Cell Transplant Complications

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT07340723
- **Lead sponsor:** Daihong Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07340723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07340723, "Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07340723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*